News

18th September 2017
Cambridge, UK, 18th September 2017 / Cypralis, a life sciences company focused on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases), has been awarded ne
1st March 2017
Cambridge, UK, 1st March 2017 / Cypralis, a life sciences company focussed on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases), has been awarded fundin
10th February 2017
Cambridge, UK, 10th February 2017 / Cypralis, with colleagues from Selcia and Gilead Sciences Inc., have published in the
23rd January 2017
Cypralis, a life sciences company focused on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases), has successfully completed its Innovate UK feasibility award and has been awarded new funding by Innovate UK, the UK’s innovation agency, under its BioMedical Catalyst competition.
7th November 2016
Cypralis was spun out from parent company Selcia to exploit its extensive expertise and know-how in targeting a large family of protein targets involved in many acute and chronic diseases.
13th July 2016
Cypralis, a life sciences company focussed on the discovery of novel therapeutics based on modulation of peptidyl-prolyl isomerases (PPIases) has acquired a portfolio of cyclophilin inhibitor assets from SCYNEXIS Inc, a NASDAQ-listed company headquartered in New Jersey, USA.
2nd March 2016
Cypralis appoints Dr Michael Peel as Chief Scientific Officer.
27th January 2016
Neurodegenerative diseases are defined as hereditary and sporadic conditions characterised by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral structures of the nervous system
7th December 2015
Ongar, UK, 7th December 2015 / Cypralis, a life sciences company focussed on the discovery of therapeutics for the modulation of peptidyl-prolyl isomerases (PPIases), has entered into a collaboration with Janssen Pharmaceuticals I

Pages